A comparison of menotropin, highly-purified menotropin and follitropin alfa in cycles of intracytoplasmic sperm injection

Table 6 Live birth outcomes of the 865 ICSI cycles.

	hMG	HP-hMG	r-hFSH	p value
Cycles with live births, n	73	107	71
Single, n (%)	50 (68.5)	68 (63.5)	46 (64.8)	0.57
Twins, n (%)	18 (24.7)	34 (31.8)	22 (31.0)	0.59
Triplets, n (%)	5 (6.8)	5 (4.7)	3 (4.2)	0.89
Mean gestational age, weeks (± SD)
Single	36.5 (± 3.6)^a	38.1 (± 2.1)^b	38.3 (± 2.3)^c	0.01 (^a vs ^{b, c})
Twins	35.0 (± 0.8)^a	35.1 (± 3.0)^b	37.3 (± 2.7)^c	0.03 (^{a, b} vs ^c)
Triplets	29.3 (± 3.5)^a	31.1 (± 3.4)^b	34.0 (± 0.0)^c	0.03 (^a vs ^c)
Mean weight, g (± SD)
Single	2882 (± 703)	3064 (± 470)	3024 (± 334)	0.09
Twins	2352 (± 436)^a	2067 (± 614)^b	2230 (± 715)^c	0.01 (^a vs ^b)
Triplets	1250 (± 329)^a	1470 (± 448)^b	1747 (± 196)^c	0.03 (^a vs ^c)

Cycles with live births in relation to the parity and gestational outcomes of the babies from 865 ICSI cycles with menotropin (hMG), highly-purified menotropin (HP-hMG) or follitropin alfa (r-hFSH) used for COH. Overall and parity-stratified outcomes are presented.
COH, controlled ovarian hyperstimulation; hMG, human menopausal gonadotropin; HP-hMG, highly-purified hMG; ICSI, intracytoplasmic sperm injection; r-hFSH, recombinant human follicle-stimulating hormone; SD, standard deviation.

ISSN: 1477-7827